Transition from IBD Audit to IBD Registry
In 2016 the national IBD audit is coming to an end, and the IBD Registry is becoming the vehicle for the biological therapies audit and quality improvement programme. Teams can participate using a choice of data entry systems including some local systems they may have in their hospital already.
The IBD Registry provides the infrastructure to capture pseudonymised IBD patient data and link it with routinely collected NHS hospital statistics. Bringing this data together for the first time will:
- Drive continuous improvement in patient care and access to care across the UK
- Inform commissioning and service design
- Improve our understanding of long term outcomes
- Provide local, regional & national data in order to better define the pattern of ulcerative colitis and Crohn’s disease
- Support IBD research
Being part of the IBD Registry will give participating teams access to better local data to manage their biologics patients and IBD service more effectively, while patients, clinicians and the NHS will all benefit from national audit of the safety and appropriate use of biologics and biosimilars. In time, the combined UK data will become a unique resource for real-world clinical effectiveness and health economic studies in IBD care.
The audit and Registry teams are working closely to manage the transition and you can find a list of frequently asked questions here:
FAQs on IBD programme transition to Registry
NHS England’s Quality Accounts
The IBD Registry’s IBD Biologics Audit was part of NHS England’s Quality Accounts programme for 2017/18 and has been included in the programme for 2018/19. You can read more about NHS England’s Quality Accounts here.
Find out more about:
Important information for Registry-participating clinical teams: with the COVID-19 outbreak, to ease pressure on clinical teams we postponed the last (April) submission deadline. The next submission deadline is 10 July 2020 for data to the end of June, including all...
Over 32,000 people in the UK with IBD have self-assessed their risk since launch on the 1 April 2020. Between them, they have identified the 175 hospitals (Trusts and Health Boards) that provide them with care, and the data has been shared back to their doctors which...
Given the special circumstances putting pressure on IBD teams and wider health services, we have created some in-depth articles below in an easy to read format: Switchers: Changing originator biologic to biosimilar Changing originator biologic to biosimilar With many...
With the COVID-19 outbreak and the resulting pressure on IBD clinical teams, the next IBD Registry data submission (planned beginning of April) has been relaxed, so that the next data submission dates will be 10 July followed by 9 Oct 2020. IBD clinical teams should...
Huge congratulations to IBD clinical teams across the country - we have surpassed the 60,000 patient record mark. At time of writing we hold 63,181 records. 62 IBD teams submitted for this last quarter, 24% more than the same period last year. Figure: number of...